A Phase II Study of the Combination of Ruxolitinib or Dasatinib with Chemotherapy in Patients with Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL)
Please note: If you are reading and signing this form on behalf of a potential participant, please note: Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant. The goal of this clinical research study is to learn if ruxolitinib or dasatinib in combination with chemotherapy can help to control Philadelphia Chromosome (Ph)-like acute lymphoblastic leukemia (ALL). The safety of these drug combinations will also be studied.
Treatment Location: N/A
IRB Review and Approval Date: 07/15/2015
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: